[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100351800":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":26,"responsibleParty":40,"collaborators":11,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":11,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":11,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":11,"overallStatus":62,"whyStopped":11,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"NImmune Biopharma","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR",null,[13],"Drug: Placebo",{"label":15,"type":16,"description":11,"interventionNames":17},"BT-11","EXPERIMENTAL",[18],"Drug: BT-11",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Oral tablet",[9],{"type":21,"name":15,"description":22,"armGroupLabels":25,"otherNames":11},[15],[27],{"facility":28,"status":11,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":11},"Site","Blacksburg","Virginia","24060","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-80.41394,37.22957,{"lat":38,"lon":37},{"type":41,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100351800","phase-1-safety-tolerability-and-pharmacokinetics-of-oral-bt-11-in-healthy-adult-male-and-female-volunteers-100351800",false,"NCT03860571","Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers","A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers","Key Inclusion Criteria:\n\n1. Healthy male and female volunteers aged 18 to 65 years, inclusive.\n2. Body weight 65 - 85 kg.\n3. Volunteer has read, confirmed understanding of, and signed the written informed consent form after the nature of the study and all essential elements of the informed consent document have been fully explained and all of the Volunteer's questions have been answered to his or her satisfaction, prior to initiation of any study procedures.\n\nKey Exclusion Criteria:\n\n1\\. Any clinically significant abnormality identified in the screening history, physical examination (including Vital Signs), laboratory testing, or electrocardiographic testing. Repeat testing of vital signs to confirm the value is allowed. Up to two repeat tests are permitted to confirm eligibility.",true,"ALL","18 Years","65 Years",{"count":54,"type":55},70,"ACTUAL","INTERVENTIONAL",[58],"PHASE1","Study type: Interventional Description of intervention(s) \u002F exposure\n\nFor single ascending dose, five dose target ranges of BT-11 (depending on body weight the doses in each cohort will be 5.9 - 7.7 mg\u002Fkg; 18.9 - 25.0 mg\u002Fkg; 44.3 - 50.0 mg\u002Fkg; 68.5 - 75 mg\u002Fkg and 94.2 - 100.0 mg\u002Fkg) will be evaluated, based on subject's weight on Day 1.\n\nFor multiple ascending dose (once daily for 7 days), three dose target ranges of BT-11 (depending on body weight the doses in each cohort will be 5.9 - 7.7 mg\u002Fkg; 44.3 - 50.0 mg\u002Fkg; and 94.2 - 100.0 mg\u002Fkg) will be evaluated, based on subject's weight on Day 1.\n\nWhite tablets containing 500 mg BT-11 or matching placebo tablets will be dispensed.\n\nSingle ascending dose duration of administration will be once. For multiple ascending dose it will be up to 7 days.\n\nThe mode administration will be oral tablet. Compliance and adherence to the intervention will be performed based on the tablet return, tablet not consumed by the subject.\n\nThe safety monitoring committee will evaluate safety at conclusion of single ascending cohort 2 prior to the commencement of dosing for the multiple ascending dose.",[61],"Normal Healthy Volunteers","COMPLETED","2023-06-06",{"date":65,"type":55},"2023-06-07",{"date":67,"type":55},"2018-07-06",{"date":69,"type":55},"2018-12-13",{"name":5,"class":6},1]